Kirin bacteria may prevent dermatitis

Related tags Lactobacillus Atopic dermatitis

Japan's Kirin Brewery says it has new animal and human clinical
data showing that one of its lactic acid bacteria strains is
effective at preventing atopic dermatitis.

The company presented results last year showing that Lactobacillus paracasei​ KW3110 was effective against atopic dermatitis in an animal model.

It says that new animal results, to be presented this week to the Japan Society for Bioscience, Biotechnology, and Agrochemistry (JSBBA), have found the strain to both prevent the occurrence of atopic dermatitis and improve symptoms in existing atopic dermatitis.

The study also showed that Lactobacillus KW was more effective than Lactobacillus rhamnosus GG (hereafter LGG), a different strain of lactobacillus that has already been shown to act against similar skin conditions, according to a company release.

In a further study, 84 people with symptoms of atopic dermatitis were divided into two groups. One group was provided with Lactobacillus KW and the control group was given a placebo. Observation over 12 weeks showed a significant improvement in symptoms such as itchiness and skin rash in the group receiving Lactobacillus KW. Comparison with the placebo control group showed a higher degree of improvement in itchiness.

The results suggest that Lactobacillus KW functions to control atopic dermatitis not only in animals but also in humans.

It is thought that the bacteria improves the balance of two lymphocytes, known as Th1 and Th2, linked to allergies.

The results of the human trial will be presented on 3 June 2005 at a spring clinical conference being held by the Japanese Society of Allergology.

Related news

Show more

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Related suppliers

Follow us

Products

View more

Webinars